Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MGR003
MIFTS: 51

Migraine with Aura

Categories: Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Migraine with Aura

About this section

MalaCards integrated aliases for Migraine with Aura:

Name: Migraine with Aura 12 6 44 15 17 70
Migraine with Typical Aura 70
Classic Migraine 12

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10024
ICD9CM 34 346.0
MeSH 44 D020325
NCIt 50 C117005
SNOMED-CT 67 155047002
ICD10 32 G43.1
UMLS 70 C0154723 C1735856
Sources

Summaries for Migraine with Aura

About this section
Disease Ontology : 12 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary : Migraine with Aura, also known as migraine with typical aura, is related to migraine, familial hemiplegic, 1 and familial hemiplegic migraine, and has symptoms including headache An important gene associated with Migraine with Aura is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are cAMP signaling pathway and Synaptic vesicle cycle. The drugs Milnacipran and Levomilnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Sources

Related Diseases for Migraine with Aura

About this section

Diseases in the Migraine with Aura family:

Migraine with Aura 7 Migraine with Aura 9

Diseases related to Migraine with Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 migraine, familial hemiplegic, 1 32.7 SLC6A4 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
2 familial hemiplegic migraine 32.7 SCN1A PRRT2 NOTCH3 KCNK18 CACNA1A ATP1A2
3 migraine, familial hemiplegic, 2 32.7 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
4 migraine, familial hemiplegic, 3 32.6 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
5 migraine with or without aura 1 32.4 SLC6A4 SLC6A3 SCN1A PRRT2 NOTCH3 MTHFR
6 headache 32.2 SLC6A4 SCN1A NOTCH3 CACNA1A ATP1A2
7 migraine without aura 31.9 SLC6A4 SCN1A NOTCH3 MTHFR KCNK18 FHL5
8 patent foramen ovale 31.8 SCN1A NOTCH3 MTHFR ATP1A2 ACE
9 sporadic hemiplegic migraine 31.2 SCN1A CACNA1A ATP1A2
10 familial or sporadic hemiplegic migraine 31.1 SCN1A PRRT2 CACNA1A ATP1A2
11 restless legs syndrome 31.1 SLC6A4 SLC6A3 DRD2 CACNA1A
12 depression 31.0 SLC6A4 NOTCH3 HTR2C
13 seizure disorder 30.9 SCN1A PRRT2 FLNA ATP1A2
14 tic disorder 30.7 SLC6A4 SLC6A3 DRD2
15 generalized anxiety disorder 30.7 SLC6A4 SLC6A3 DRD2
16 epilepsy, idiopathic generalized 30.6 SCN1A PRRT2 CACNA1A ATP1A2
17 epilepsy 30.6 SLC6A3 SCN1A PRRT2 MTHFR FLNA CACNA1A
18 mental depression 30.5 SLC6A4 SLC6A3 HTR2C HTR1D HTR1B DRD2
19 mood disorder 30.5 SLC6A4 SLC6A3 HTR2C HTR1B DRD2 ACE
20 bipolar disorder 30.5 SLC6A4 SLC6A3 MTHFR HTR2C HTR1B DRD2
21 major depressive disorder 30.5 SLC6A4 SLC6A3 MTHFR HTR2C HTR1D HTR1B
22 anxiety 30.5 SLC6A4 SLC6A3 HTR2C HTR1D HTR1B DRD2
23 dystonia 30.4 SLC6A3 PRRT2 DRD2 DBH CACNA1A
24 pure autonomic failure 30.3 DBH ACE
25 migraine with aura 7 11.6
26 migraine with aura 9 11.5
27 epilepsy, familial temporal lobe, 4 11.5
28 migraine with or without aura 13 11.2
29 familiar or sporadic hemiplegic migraine 11.2
30 hemiplegia 10.5 SCN1A CACNA1A ATP1A2
31 inhibited male orgasm 10.5 SLC6A4 SLC6A3 HTR2C
32 cyclothymic disorder 10.5 SLC6A4 HTR2C DRD2
33 psychosexual disorder 10.5 SLC6A4 HTR2C HTR1B
34 sexual disorder 10.5 SLC6A4 HTR2C ACE
35 spinocerebellar ataxia 6 10.5 SCN1A CACNA1A ATP1A2
36 amphetamine abuse 10.5 SLC6A4 SLC6A3 HTR1B
37 alcohol-induced mental disorder 10.5 SLC6A4 DRD2
38 episodic ataxia, type 2 10.5 SCN1A CACNA1A ATP1A2
39 dysthymic disorder 10.5 SLC6A4 SLC6A3 HTR2C
40 delusional disorder 10.5 SLC6A3 HTR2C DRD2
41 schizophreniform disorder 10.5 SLC6A3 HTR2C DRD2
42 barbiturate dependence 10.5 SLC6A4 DBH
43 phobic disorder 10.5 SLC6A4 SLC6A3 DRD2
44 torticollis 10.5 PRRT2 DRD2 CACNA1A
45 lingual-facial-buccal dyskinesia 10.5 SLC6A3 HTR2C DRD2
46 heroin dependence 10.5 SLC6A4 SLC6A3 DRD2
47 episodic ataxia, type 5 10.5 CACNA1A ATP1A2
48 substance-induced psychosis 10.5 SLC6A4 SLC6A3 HTR2C DRD2
49 autonomic nervous system disease 10.5 SCN1A DBH ACE
50 opiate dependence 10.5 SLC6A4 SLC6A3 DRD2

Comorbidity relations with Migraine with Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with Aura:



Diseases related to Migraine with Aura
Sources

Symptoms & Phenotypes for Migraine with Aura

About this section

UMLS symptoms related to Migraine with Aura:


headache

MGI Mouse Phenotypes related to Migraine with Aura:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
2 growth/size/body region MP:0005378 10.25 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
3 endocrine/exocrine gland MP:0005379 10.13 ACE CACNA1A DBH DRD2 FHL5 HTR1B
4 mortality/aging MP:0010768 10.13 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
5 integument MP:0010771 10.02 ATP1A2 CACNA1A DBH DRD2 HTR2C MTHFR
6 nervous system MP:0003631 10 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
7 muscle MP:0005369 9.91 ATP1A2 CACNA1A DRD2 HTR1B HTR2C NOTCH3
8 normal MP:0002873 9.65 ATP1A2 CACNA1A DBH DRD2 FLNA HTR1D
9 reproductive system MP:0005389 9.36 ACE CACNA1A DRD2 FHL5 FLNA HTR1B
Sources

Drugs & Therapeutics for Migraine with Aura

About this section

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
2
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9 Psychotropic Drugs Phase 4
10 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
11 Antidepressive Agents Phase 4
12 Gastrointestinal Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Narcotics Phase 4
15 Dopamine Agents Phase 4
16 Dopamine Antagonists Phase 4
17 Anesthetics Phase 4
18 Antiemetics Phase 4
19 Anesthetics, General Phase 4
20 Anesthetics, Intravenous Phase 4
21 Serotonin Receptor Agonists Phase 4
22 Hypoglycemic Agents Phase 4
23 Ketorolac Tromethamine Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Analgesics Phase 4
26 Antirheumatic Agents Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4
30 Dexketoprofen trometamol Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
32
Sumatriptan Approved, Investigational Phase 3 103628-46-2 5358
33
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
34
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
35
Promethazine Approved, Investigational Phase 3 60-87-7 4927
36
Rizatriptan Approved Phase 3 145202-66-0, 144034-80-0 5078
37
Caffeine Approved Phase 3 58-08-2 2519
38
Candesartan cilexetil Approved Phase 2, Phase 3 145040-37-5 2540
39
Angiotensin II Approved, Investigational Phase 2, Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198
40
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
41
Ergotamine Approved Phase 3 113-15-5 8223
42
Dihydroergotamine Approved, Investigational Phase 3 6190-39-2, 511-12-6 10531
43
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
44
Candesartan Experimental Phase 2, Phase 3 139481-59-7 2541
45 Vasoconstrictor Agents Phase 3
46 Serotonin 5-HT1 Receptor Agonists Phase 3
47 Antihypertensive Agents Phase 3
48 Anti-Arrhythmia Agents Phase 3
49 Adrenergic Antagonists Phase 3
50 Adrenergic beta-Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
3 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
4 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
5 Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase. Completed NCT03689361 Phase 4
6 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
7 A Randomized-controlled Study; Comparison of the Effectiveness of Intravenous Ibuprofen and Intravenous Dexketoprofen in the Treatment of Migraine-related Headache in the Emergency Department Not yet recruiting NCT04533568 Phase 4 Ibuprofen 400 mg;Dexketoprofen
8 A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
9 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00236509 Phase 3 topiramate
10 A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura) Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
11 EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Completed NCT03901482 Phase 3 Dihydroergotamine;Placebos
12 A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
13 A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00131443 Phase 2, Phase 3 Topiramate
14 Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache Completed NCT00449540 Phase 3
15 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00231595 Phase 3 topiramate
16 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
17 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
18 Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
19 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET) Completed NCT00387881 Phase 3 sumatriptan succinate / naproxen sodium;Placebo
20 A 12-week Prospective, Double-blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis. Completed NCT00258609 Phase 3 Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection
21 An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Recruiting NCT04406649 Phase 3 Dihydroergotamine
22 Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room Not yet recruiting NCT04726592 Phase 3 Clorazepate Dipotassium;Placebo;Ketoprofen;Metoclopramide
23 Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
24 A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura Unknown status NCT00877838 Phase 2 NXN-188;Placebo
25 Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches. Unknown status NCT03220113 Phase 1, Phase 2
26 Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
27 An Open-Label Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00158002 Phase 2 Topiramate
28 A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura Completed NCT00332007 Phase 2 Tonabersat;Placebo
29 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
30 A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura Completed NCT00920686 Phase 2 NXN-188;placebo;sumatriptan succinate
31 Effects of DFN-15 on Migraine With Allodynia Completed NCT03472378 Phase 2 DFN-15
32 Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
33 Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura Completed NCT00959751 Phase 2 NXN-188;Placebo
34 Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura Not yet recruiting NCT04063540 Phase 2 Amiloride;Placebos
35 Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial) Terminated NCT00505570 Phase 2
36 A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
37 A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects Completed NCT03874832 Phase 1 Dihydroergotamine
38 A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura Unknown status NCT00893594 sumatriptan with naprosyn;placebo
39 Migraine Characteristics in Patients Undergoing PFO (Patent Foramen Ovale) Closure: Evaluation of a Specific Risk Profile Unknown status NCT03521193
40 MR-Angiografi (MRA) og MR-Spektroskopi (MRS) Hos Raske forsøgspersoner og Patienter Med migræne Uden Aura Provokeret Med Calcitonin Gen-relateret Peptid (CGRP) og Sildenafil Unknown status NCT03143465 Calcitonin Gene-Related Peptide;Sildenafil;Placebo
41 Functional MRI and MRA in Migraine With Aura Unknown status NCT01388894
42 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
43 Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI Unknown status NCT02549898 Feraheme;Cilostazol
44 Multiparametric Diagnostic Model of Thick-section Clinical-quality MRI Data in Detecting Migraine Without Aura Unknown status NCT03570086
45 Cortical Reorganisation in Patients With Primary Headache Disorders Unknown status NCT00263991
46 Mindfulness and Mechanisms of Pain Processing in Adults With Migraines Completed NCT02695498
47 Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins Completed NCT02047695
48 Open, Randomised, Multi-Centre, Cross-Over Study to Investigate the Efficacy of the Migraid Device Compared With No Device Treatment in the Acute, Early Treatment of Migraine With Typical Aura Completed NCT00126035
49 Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients Completed NCT04012047 Levcromakalim;Saline
50 Transcriptomic and Biochemical Changes During Spontaneous Attacks of Migraine With Aura and Migraine Without Aura Completed NCT02468622

Search NIH Clinical Center for Migraine with Aura

Cochrane evidence based reviews: migraine with aura

Sources

Genetic Tests for Migraine with Aura

About this section
Sources

Anatomical Context for Migraine with Aura

About this section

MalaCards organs/tissues related to Migraine with Aura:

40
Brain, Endothelial, Cortex, Pituitary, Heart, Eye, Occipital Lobe
Sources

Publications for Migraine with Aura

About this section

Articles related to Migraine with Aura:

(show top 50) (show all 2308)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial. 61
33789774 2021
3
Relationship between non-headache symptoms and right to left shunt in episodic migraine. A single-center cross-sectional study. 61
33775344 2021
4
Association Between Hemostatic Profile and Migraine: A Mendelian Randomization Analysis. 61
33795393 2021
5
Pediatric Episodic Migraine with Aura: A Unique Entity? 61
33802676 2021
6
Migraine: Calcium Channels and Glia. 61
33799975 2021
7
Does menstruation-related headache occur exclusively in women with migraine? 61
33721258 2021
8
Opening of ATP sensitive potassium channels causes migraine attacks with aura. 61
33768245 2021
9
Atrial fibrillation and migraine with aura in young adults with ischemic stroke. 61
33200948 2021
10
Retinal nerve fiber layer changes in migraine: a systematic review and meta-analysis. 61
33439389 2021
11
Can you have a migraine aura without knowing it? 61
33661163 2021
12
Familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2. 61
33711927 2021
13
Painless Thyroiditis Presenting with Headache. 61
33678752 2021
14
Cortical spreading depolarization and ketamine: a short systematic review. 61
33610431 2021
15
Cardiac sources of cerebral embolism in people with migraine. 61
32979886 2021
16
The presence of aura is not related to changes in the cervical performance and mobility of patients with migraine. 61
33288453 2021
17
Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine. 61
33573735 2021
18
Non-canonical glutamate signaling in a genetic model of migraine with aura. 61
33321071 2021
19
Real-world efficacy, tolerability, and safety of ubrogepant. 61
33547676 2021
20
TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons. 61
33525904 2021
21
Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers. 61
33377176 2021
22
Prevalence and grade of RLS in migraine: A prospective study of 251 migraineurs by synchronous test of c-TTE and c-TCD. 61
33530208 2021
23
Serum lipid abnormalities in migraine: A meta-analysis of observational studies. 61
33398889 2021
24
The Efficacy of Percutaneous Patent Foramen Ovale Closure on Migraine: a Meta-Analysis of Randomized Controlled Trials and Observational Studies. 61
33748272 2021
25
[Migraine with typical aura without headache; first presentation at older age]. 61
33560603 2021
26
Migraine and cardiovascular risk factors: A clinic-based study. 61
33260087 2021
27
The epidemiology of primary headaches in patients with multiple sclerosis. 61
33295123 2021
28
Thrombophilic alterations, migraine, and vascular disease: results from a case-control study. 61
33471261 2021
29
Occipital ischaemic stroke after visual snow phenomenon - a case report. 61
33435707 2021
30
Cortical Spreading Depression Phenomena Are Frequent in Ischemic and Traumatic Penumbra: A Prospective Study in Patients With Traumatic Brain Injury and Large Hemispheric Ischemic Stroke. 61
31702708 2021
31
Insights for temporomandibular disorders management: From psychosocial factors to genetics-A case report. 61
33152157 2021
32
Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study. 61
33269953 2020
33
The potential danger of blocking CGRP for treating migraine in CADASIL patients. 61
32660269 2020
34
Chromosome 15q BP4-BP5 Deletion in a Girl with Nocturnal Frontal Lobe Epilepsy, Migraine, Circumscribed Hypertrichosis, and Language Impairment. 61
33659201 2020
35
Risk of Retinal Artery Occlusion in Patients with Migraine. 61
33359716 2020
36
Intravenous sodium valproate for acute migraine in the emergency department: A meta-analysis. 61
32740903 2020
37
Acute monocular oligemia in a patient with migraine with aura demonstrated using OCT-angiography: A case report. 61
33356532 2020
38
Cysteine-Altering NOTCH3 Variants Are a Risk Factor for Stroke in the Elderly Population. 61
33161844 2020
39
[123I]-IMP single-photon emission computed tomography imaging in visual snow syndrome: A case series. 61
32791921 2020
40
A review of diving practices and outcomes following the diagnosis of a persistent (patent) foramen ovale in compressed air divers with a documented episode of decompression sickness. 61
33325017 2020
41
Transcranial Doppler Evaluation of the Cerebral Vasculature in Women Patients who Have Migraine with Aura. 61
32918482 2020
42
Evaluation of retinal vessel density and choriocapillaris flow in migraine patients with and without aura. 61
32591975 2020
43
Rates of Vascular Events in Patients With Migraine: A MarketScan® Database Retrospective Cohort Study. 61
33141461 2020
44
Migraine variants: Nursing considerations. 61
33048855 2020
45
Migraine With Exclusive Olfactory Aura: Case Report and Literature Review. 61
33205440 2020
46
Branch Retinal Vein Occlusion and Venous Abnormalities in CADASIL. 61
33181727 2020
47
Primary headache subtypes and thyroid dysfunction: Is there any association? 61
33146240 2020
48
Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit. 61
33167711 2020
49
NMDA receptors sustain but do not initiate neuronal depolarization in spreading depolarization. 61
32890774 2020
50
A comparison of methods to determine patent foramen ovale size. 61
31872955 2020
Sources

Variations for Migraine with Aura

About this section

ClinVar genetic disease variations for Migraine with Aura:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLNA GRCh37/hg19 Xq28(chrX:153575976-153586768) copy number loss Pathogenic 523300 GRCh37: X:153575976-153586768
GRCh38:
2 overlap with 2 genes GRCh37/hg19 Xq28(chrX:153588672-153609996) copy number gain Pathogenic 523301 GRCh37: X:153588672-153609996
GRCh38:
3 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg) SNV Pathogenic 812745 rs1555729455 GRCh37: 19:15302816-15302816
GRCh38: 19:15192005-15192005
4 NOTCH3 NM_000435.3(NOTCH3):c.1162T>C (p.Cys388Arg) SNV Likely pathogenic 812743 rs1599391938 GRCh37: 19:15300114-15300114
GRCh38: 19:15189303-15189303
5 NOTCH3 NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser) SNV Likely pathogenic 812744 rs1599391986 GRCh37: 19:15300140-15300140
GRCh38: 19:15189329-15189329
6 DGUOK NM_080916.3(DGUOK):c.278G>A (p.Gly93Glu) SNV Uncertain significance 523553 rs1553403624 GRCh37: 2:74173868-74173868
GRCh38: 2:73946741-73946741
7 DGUOK NM_080916.3(DGUOK):c.65C>T (p.Pro22Leu) SNV Uncertain significance 523554 rs757962437 GRCh37: 2:74154102-74154102
GRCh38: 2:73926975-73926975
Sources

Expression for Migraine with Aura

About this section
Search GEO for disease gene expression data for Migraine with Aura.
Sources

Pathways for Migraine with Aura

About this section

Pathways related to Migraine with Aura according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
cAMP signaling pathway 36
12.04 HTR1D HTR1B DRD2 ATP1A2
2
Synaptic vesicle cycle 36
Show member pathways
 11.74 SLC6A4 SLC6A3 CACNA1A ATP1A2
3
Serotonergic synapse 36
11.61 SLC6A4 HTR2C HTR1D HTR1B CACNA1A
4
Monoamine GPCRs 1
Show member pathways
 11.6 HTR2C HTR1D HTR1B DRD2
5
Monoamine Transport 1
Show member pathways
 11.18 SLC6A4 SLC6A3 DBH
6
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.73 HTR2C DRD2
7
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.7 SLC6A4 HTR2C HTR1D HTR1B
8
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.38 SLC6A4 SLC6A3 HTR1B DRD2 DBH
Sources

GO Terms for Migraine with Aura

About this section

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.21 SLC6A4 SLC6A3 SCN1A PRRT2 NOTCH3 KCNK18
2 plasma membrane GO:0005886 10.1 SLC6A4 SLC6A3 SCN1A PRRT2 NOTCH3 KCNK18
3 integral component of plasma membrane GO:0005887 10.02 SLC6A4 SLC6A3 KCNK18 HTR2C HTR1D HTR1B
4 neuronal cell body GO:0043025 9.83 SLC6A3 SCN1A FLNA CACNA1A ATP1A2
5 integral component of postsynaptic membrane GO:0099055 9.58 SLC6A4 SLC6A3 DRD2
6 dopaminergic synapse GO:0098691 9.46 SLC6A3 DRD2
7 G protein-coupled serotonin receptor complex GO:0098666 9.32 HTR2C HTR1B
8 synapse GO:0045202 9.28 SLC6A4 PRRT2 MTHFR HTR2C HTR1D DRD2
9 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 HTR1B DRD2
10 serotonergic synapse GO:0099154 9.16 SLC6A4 HTR1B

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.83 SLC6A4 SLC6A3 MTHFR HTR2C DRD2
2 cation transmembrane transport GO:0098655 9.77 SCN1A CACNA1A ATP1A2
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.72 HTR2C HTR1D HTR1B
4 response to iron ion GO:0010039 9.65 SLC6A3 DRD2
5 behavior GO:0007610 9.65 HTR2C HTR1B
6 visual learning GO:0008542 9.65 DRD2 DBH ATP1A2
7 chemical synaptic transmission GO:0007268 9.65 HTR2C HTR1D HTR1B DBH CACNA1A
8 regulation of presynaptic cytosolic calcium ion concentration GO:0099509 9.64 HTR1B CACNA1A
9 negative regulation of cytosolic calcium ion concentration GO:0051481 9.64 DRD2 ATP1A2
10 neurotransmitter biosynthetic process GO:0042136 9.63 SLC6A4 SLC6A3
11 G protein-coupled receptor internalization GO:0002031 9.63 HTR1B DRD2
12 response to cocaine GO:0042220 9.63 SLC6A3 HTR1B DRD2
13 neuromuscular process controlling posture GO:0050884 9.62 SCN1A PRRT2
14 prepulse inhibition GO:0060134 9.62 SLC6A3 DRD2
15 neurotransmitter uptake GO:0001504 9.61 SLC6A3 ATP1A2
16 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 HTR1B DRD2
17 regulation of behavior GO:0050795 9.59 HTR1D HTR1B
18 dopamine catabolic process GO:0042420 9.58 SLC6A3 DBH
19 monoamine transport GO:0015844 9.58 SLC6A4 SLC6A3
20 blood vessel remodeling GO:0001974 9.58 FLNA DBH ACE
21 behavioral response to ethanol GO:0048149 9.57 DRD2 DBH
22 adenohypophysis development GO:0021984 9.56 SLC6A3 DRD2
23 hyaloid vascular plexus regression GO:1990384 9.54 SLC6A3 DRD2
24 response to nicotine GO:0035094 9.54 SLC6A3 DRD2 ATP1A2
25 drinking behavior GO:0042756 9.52 HTR1B DRD2
26 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.51 HTR1D HTR1B
27 feeding behavior GO:0007631 9.5 HTR2C HTR1B DRD2
28 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.49 FLNA DRD2
29 sodium ion transmembrane transport GO:0035725 9.46 SLC6A4 SLC6A3 SCN1A ATP1A2
30 locomotory behavior GO:0007626 9.26 SLC6A3 HTR2C DRD2 DBH
31 vasoconstriction GO:0042310 8.8 SLC6A4 HTR1D HTR1B

Molecular functions related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.5 HTR2C HTR1D HTR1B
2 neurotransmitter transporter activity GO:0005326 9.37 SLC6A4 SLC6A3
3 monoamine transmembrane transporter activity GO:0008504 9.26 SLC6A4 SLC6A3
4 dopamine binding GO:0035240 9.16 SLC6A3 DRD2
5 G protein-coupled serotonin receptor activity GO:0004993 9.13 HTR2C HTR1D HTR1B
6 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR1D HTR1B
Sources

Sources for Migraine with Aura

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....